Lymphoma Clinical Trials in Shanghai
37 recruitingShanghai, China
Showing 1–20 of 37 trials
Recruiting
Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular Lymphoma
AstraZeneca1,018 enrolled135 locationsNCT06549595
Recruiting
Phase 2Phase 3
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
TreatmentSurvivalClassical Hodgkin Lymphoma+6 more
Children's Cancer Group, China96 enrolled1 locationNCT06563245
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Hoffmann-La Roche300 enrolled12 locationsNCT07200375
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled75 locationsNCT06084936
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
Phase 3
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Large B-cell Lymphoma
AstraZeneca420 enrolled40 locationsNCT07215585
Recruiting
Phase 1
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
Advanced Solid TumorNon-Hodgkin Lymphoma
Axter Therapeutics (Beijing) Co., Ltd78 enrolled5 locationsNCT06484985
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 2
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University25 enrolled1 locationNCT06519526
Recruiting
Phase 2
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
B-cell Non Hodgkin Lymphoma
Ruijin Hospital16 enrolled1 locationNCT06365671
Recruiting
Phase 1Phase 2
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.112 enrolled15 locationsNCT05800977
Recruiting
Early Phase 1
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
DLBCLNK/T-cell LymphomaPeripheral T-cell Lymphoma (PTCL)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine24 enrolled1 locationNCT07162012
Recruiting
Not Applicable
Universal CAR-T Cell Therapy for NHL
Non-hodgkin Lymphoma,B Cell
Bioray Laboratories6 enrolled1 locationNCT07248163
Recruiting
Phase 2
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Mantle Cell Lymphoma (MCL)
Ruijin Hospital45 enrolled1 locationNCT07199296
Recruiting
Phase 1
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
B-cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd30 enrolled3 locationsNCT07093073
Recruiting
Phase 1
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
B-cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20 enrolled2 locationsNCT07093086
Recruiting
Phase 1
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.40 enrolled2 locationsNCT07073833